Bladder Cancer VL

Bladder-Sparing Therapy vs Upfront Cystectomy: Long-Term Outcomes in BCG-Unresponsive Bladder Cancer - Jacob Taylor

Details
Jacob Taylor joins Ashish Kamat to discuss a multicenter study comparing long-term outcomes between bladder-sparing therapies and upfront radical cystectomy in BCG-unresponsive bladder cancer. Drawing from data across ten institutions in the US, Canada, and France, Dr. Taylor presents findings showing no significant difference in overall survival between the two approaches, though patients undergo...

Smoking Cessation as a Precision Cancer Care Intervention in Urologic Oncology - Richard Matulewicz

Details
Richard Matulewicz discusses implementing smoking cessation in urologic oncology practice. The discussion highlights smoking cessation as a powerful intervention that can increase overall survival by nearly two years in cancer patients. Matulewicz emphasizes that while urologists frequently encounter tobacco-related diseases, with approximately 1.3 million visits annually involving smokers, there...

BCG-Unresponsive Bladder Cancer Study Examines Risks of Bladder-Sparing Therapies for T1 Disease - Yair Lotan

Details
Yair Lotan discusses a multicenter study examining the impact of tumor stage on outcomes in BCG-unresponsive bladder cancer patients undergoing bladder-sparing therapies. Analyzing data from 401 patients across 10 centers, the research demonstrates that patients with T1 disease have significantly worse outcomes in terms of progression, metastasis, and cancer-specific survival compared to those wit...

Sequential Gemcitabine and Docetaxel Examined in BCG-Unresponsive Bladder Cancer Patients - Yair Lotan

Details
Yair Lotan joins Ashish Kamat to discuss a multicenter retrospective study comparing sequential intravesical gemcitabine and docetaxel (gem/doce) with BCG in BCG-unresponsive non-muscle invasive bladder cancer. The research examines outcomes in 299 patients over a 20-year period, finding that gem/doce is associated with improved progression-free survival, cancer-specific survival, and lower rates...

FGFR3 Inhibition in Urothelial Cancer Advances with Erdafitinib and TAR-210 Trials - Gopa Iyer

Details
Gopa Iyer joins Sam Chang to discuss FGFR3 inhibition in urothelial cancer. The discussion explores how FGFR3 alterations are more prevalent in low-grade and early-stage bladder cancer, with current treatment options centered on erdafitinib, the only FDA-approved targeted therapy for FGFR3-altered advanced disease. While erdafitinib shows efficacy, its systemic toxicity presents challenges, partic...

Cost-Effectiveness of Bladder-Sparing Treatments vs. Radical Cystectomy in BCG-Unresponsive NMIBC - David D’Andrea

Details
David D'Andrea joins Ashish Kamat to discuss a systematic review and cost-effectiveness analysis of treatment options for patients who fail BCG therapy in non-muscle-invasive bladder cancer. The study compares radical cystectomy with newer FDA-approved drugs, analyzing both costs and quality of life outcomes over a two-year period. Using Markov modeling, the research examines treatments including...

Preventing and Managing Complications of Radical Cystectomy - Hadley Wyre

Details
Hadley Wyre discusses the prevention and management of long-term complications following radical cystectomy, focusing particularly on ureteroenteric anastomotic strictures and parastomal hernias. Dr. Wyre emphasizes key surgical principles for preventing strictures, including the benefits of extensive ureteral spatulation and a no-touch technique, while recommending against endoscopic treatments i...

CISTO Trial Highlights Strategies to Boost Enrollment in Large Clinical Studies - Krupa Nathan & Angela Smith

Details
Ruchika Talwar speaks with Krupa Nathan and Angela Smith about a published paper discussing operational tactics and lessons learned from the CISTO trial, a large multi-institutional study comparing intravesical therapy and surgery for bladder cancer. The discussion highlights key strategies implemented to maximize patient enrollment across 38 clinical sites, particularly the success of CISTOquesti...

Phase II Trial Explores Gemcitabine Plus BCG for BCG-Exposed Bladder Cancer - Eugene Pietzak & Gal Wald

Details
Sam Chang hosts a discussion with Gal Wald and Eugene Pietzak about intravesical gemcitabine and BCG combination therapy for BCG-exposed non-muscle-invasive bladder cancer. The phase II trial demonstrates promising results with a 94% complete response rate at six months and 81% at twelve months using an alternating schedule of gemcitabine and BCG over ten weeks. The treatment shows a favorable tox...

Navigating Young-Onset Bladder Cancer - From Genomics to Survivor Perspectives - Ashish Kamat

Details
Shilpa Gupta and Ashish Kamat discuss the emerging focus on young-onset bladder cancer following their co-chaired session at the BCAN think tank meeting. They highlight the increasing prevalence of bladder cancer in younger patients and outline recent initiatives to address this unmet need, including establishing a consensus definition of under-50 as the age cutoff for young-onset cases. The discu...